Pilot Trial of Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Metronidazole; Neomycin; Vancomycin
- Indications Adenocarcinoma; Colorectal cancer; Intestinal cancer
- Focus Therapeutic Use
- 12 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 20 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.